MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Immune-based Therapies

Novel systemic therapy against malignant pleural mesothelioma

Translational Lung Cancer Research 2017 June [Link] Mancuso MR, Neal JW Abstract Malignant pleural mesothelioma is an aggressive tumor of the pleura with an overall poor prognosis. Even with surgical resection, for which only a subset of patients are eligible, long term disease free survival is rare. Standard first-line systemic treatment consists of a platinum […]

Comments Off on Novel systemic therapy against malignant pleural mesothelioma

Immunotherapy for malignant pleural mesothelioma: current status and future directions

Translational Lung Cancer Research 2017 June [Link] Dozier J1, Zheng H1, Adusumilli PS Abstract Malignant pleural mesothelioma (MPM) has been marked historically by poor prognosis. Current standard of care for this deadly disease results in sub-optimal improvements in overall survival (OS), which has prompted researchers to explore innovative treatment alternatives. Immunotherapy is an emerging therapeutic […]

Comments Off on Immunotherapy for malignant pleural mesothelioma: current status and future directions

Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma

Translational Lung Cancer 2017 June [Link] Wu L, de Perrot M Abstract Malignant pleural mesothelioma (MPM) is an aggressive neoplasm with poor outcome. Novel radical radiation techniques using intensity modulated radiation therapy (IMRT) have become an important component of therapy in mesothelioma. Immunotherapy also provides new therapeutic options. However, how best to integrate immunotherapy with […]

Comments Off on Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

Expert Opinion of Investigational Drugs 2017 July 6 [Epub ahead of print] [Link] Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, Mutti L Abstract INTRODUCTION: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to […]

Comments Off on Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma

Expert review of respiratory medicine 2017 June [Epub ahead of print] [Link] Marulli G, Faccioli E, Bellini A, Mammana M, Rea F Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive neoplasia. Multidisciplinary treatments, including the association of induction and/or adjuvant therapeutic regimens with surgery, have been reported to give encouraging results. Current therapeutic options […]

Comments Off on Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma

DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma

International Journal of Oncology 2017 May [Epub ahead of print] [Link] Wang H, Dai YY, Zhang WQ, Hsu PC, Yang YL, Wang YC, Chan G, Au A, Xu ZD, Jiang SJ, Wang W, Jablons DM, You L Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer for which more effective treatments are needed. In this […]

Comments Off on DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma

Induction of IL-17 production from human peripheral blood CD4+ cells by asbestos exposure

International Journal of Oncology 2017 June [Epub May 9] [Link] Maeda M, Chen Y, Lee S, Kumagai-Takei N, Yoshitome K, Matsuzaki H, Yamamoto S, Hatayama T, Ikeda M, Nishimura Y, Otsuki T Abstract We have previously reported that chronic, recurrent and low-dose exposure to asbestos fibers causes a reduction in antitumor immunity. Investigation of natural […]

Comments Off on Induction of IL-17 production from human peripheral blood CD4+ cells by asbestos exposure

Immunotherapy and radiation therapy for malignant pleural mesothelioma

Translational Lung Cancer Research 2017 April [Link] Alley EW, Katz SI, Cengel KA, Simone CB Abstract Malignant pleural mesothelioma (MPM) is a particularly aggressive thoracic malignancy with limited survival following combination chemotherapy. As a result, there has been increased interested in immunotherapy for mesothelioma, both in the first-line and salvage settings. Early investigations of interleukin-2 […]

Comments Off on Immunotherapy and radiation therapy for malignant pleural mesothelioma

Viroimmunotherapy of Thoracic Cancers

Biomedicines 2017 January [Link] Dash AS, Patel MR Abstract Thoracic cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and malignant pleural mesothelioma (MM), cause the highest rate of cancer mortality worldwide. Most of these deaths are as a result of NSCLC; however, prognoses for the other two diseases remain as some […]

Comments Off on Viroimmunotherapy of Thoracic Cancers

CAR T-cell therapy for lung cancer and malignant pleural mesothelioma

Translational Research [Epub ahead of print] [Link] Zeltsman M, Dozier J, McGee E, Ngai D, Adusumilli PS Abstract Immunotherapy is a promising field that harnesses the power of the immune system as a therapeutic agent for cancer treatment. Beneficial outcomes shown in patients with non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM) with […]

Comments Off on CAR T-cell therapy for lung cancer and malignant pleural mesothelioma